OSRH
OSR Holdings, Inc. Common StockOSRH
OSRH
About: OSR Holdings Inc is a healthcare company, dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of and potentially transformative therapies and healthcare solutions.
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
38.18% less ownership
Funds ownership: 38.53% [Q3] → 0.35% (-38.18%) [Q4]
77% less funds holding
Funds holding: 13 [Q3] → 3 (-10) [Q4]
99% less capital invested
Capital invested by funds: $16.9M [Q3] → $164K (-$16.8M) [Q4]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 10
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for OSRH.
Financial journalist opinion
Based on 4 articles about OSRH published over the past 30 days
Neutral
PRNewsWire
1 week ago
Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology
SEOUL, South Korea , April 9, 2025 /PRNewswire/ -- Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international patent for its protein-based osteoarthritis treatment technology, marking a significant step in its expansion into the global market. Activin/BMP7 Chimera Protein Technology Registered in China Darnatein has officially registered a patent with the China National Intellectual Property Administration (CNIPA) for the core technology behind its break-through disease-modifying osteoarthritis drug (DMOAD) lead drug candidate, DRT-101.
Neutral
PRNewsWire
2 weeks ago
OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies
SEOUL, South Korea , April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund ("Innovation Fund"). Under this agreement, OSR has the right, but not the obligation, to sell up to $80 million in common stock to Innovation Fund over time, which will prospectively provide OSR with critical funding to accelerate its mission of improving patient outcomes worldwide.
Neutral
PRNewsWire
3 weeks ago
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 BASEL, Switzerland , March 26, 2025 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma (GBM). The trial was part of a collaboration with Merck KGaA, Darmstadt, Germany.
Neutral
PRNewsWire
4 weeks ago
OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer
BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline.
Neutral
PRNewsWire
2 months ago
OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination
OSR Holdings, Inc. to Begin Trading on the Nasdaq Stock Market LLC on Tuesday, February 18, 2025 Under the symbol "OSRH" SEOUL, South Korea , Feb. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (formerly Bellevue Life Sciences Acquisition Corp. (the "Company")) and OSR Holdings Co., Ltd. ("OSR") announced today the completion of their business combination (the "Business Combination").
Charts implemented using Lightweight Charts™